Den Europæiske Union - dansk - EMA (European Medicines Agency)

roche registration gmbh - baloxavir marboxil - influenza, human - antivirale midler til systemisk anvendelse - treatment of influenzaxofluza is indicated for the treatment of uncomplicated influenza in patients aged 1 year and above. post exposure prophylaxis of influenzaxofluza is indicated for post-exposure prophylaxis of influenza in individuals aged 1 year and above. xofluza should be used in accordance with official recommendations.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

roche registration gmbh - pertuzumab, trastuzumab - bryst neoplasmer - antineoplastiske midler - early breast cancer (ebc)phesgo is indicated for use in combination with chemotherapy in:the neoadjuvant treatment of adult patients with her2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrencethe adjuvant treatment of adult patients with her2-positive early breast cancer at high risk of recurrencemetastatic breast cancer (mbc)phesgo is indicated for use in combination with docetaxel in adult patients with her2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-her2 therapy or chemotherapy for their metastatic disease.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

roche registration gmbh  - risdiplam - muskelatrofi, spinal - andre midler mod forstyrrelser i muskel-skeletsystemet - evrysdi is indicated for the treatment of 5q spinal muscular atrophy (sma) in patients with a clinical diagnosis of sma type 1, type 2 or type 3 or with one to four smn2 copies.

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

egis pharmaceuticals plc - deferasirox - filmovertrukne tabletter - 180 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

egis pharmaceuticals plc - deferasirox - filmovertrukne tabletter - 360 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

egis pharmaceuticals plc - deferasirox - filmovertrukne tabletter - 90 mg

Den Europæiske Union - dansk - EMA (European Medicines Agency)

roche registration gmbh  - pralsetinib - carcinom, ikke-småcellet lunge - antineoplastiske midler - gavreto is indicated as monotherapy for the treatment of adult patients with rearranged during transfection (ret) fusion-positive advanced non-small cell lung cancer (nsclc) not previously treated with a ret inhibitor.

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

egis pharmaceuticals plc - paliperidonpalmitat - depotinjektionsvæske, suspension i fyldt injektionssprøjte - 100+150 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

egis pharmaceuticals plc - paliperidonpalmitat - depotinjektionsvæske, suspension i fyldt injektionssprøjte - 100 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

egis pharmaceuticals plc - paliperidonpalmitat - depotinjektionsvæske, suspension i fyldt injektionssprøjte - 150 mg